It should also be noted that, from a methodological perspective, the model used (Cox with stratification by cardiovascular risk class of the trials, i.e., SURPASS-4: high risk, and all others: low risk) requires various assumptions, including the homogeneity of the relative effect of tirzepatide treatment on MACE regardless of the baseline cardiovascular risk level of the patients
This may not reflect longer-term adoption patterns as payer coverage, prescribing familiarity, and patient demand evolve
For an updated comparison, the cagrilintide vs retatrutide comparison covers the head-to-head data
For men, the hormonal shift is generally less impactful on hair because male-pattern hair loss is already driven by DHT sensitivity in genetically predisposed follicles regardless of body composition
The cost calculator helps project total stacking expenses
Aesthetic clinics